Contents lists available at ScienceDirect



### Journal of the Neurological Sciences



journal homepage: www.elsevier.com/locate/jns

## Effects of multimodal balance training supported by rhythmical auditory stimuli in people with advanced stages of Parkinson's disease: a pilot randomized clinical trial

Check for updates

Tamine T.C. Capato<sup>a,b,\*</sup>, Jorik Nonnekes<sup>c,d</sup>, Nienke M. de Vries<sup>a</sup>, Joanna IntHout<sup>e</sup>, Egberto R. Barbosa<sup>b</sup>, Bastiaan R. Bloem<sup>a</sup>

<sup>a</sup> Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Centre of Expertise for Parkinson & Movement Disorders, Nijmegen, the Netherlands

<sup>b</sup> University of São Paulo, Department of Neurology, Movement Disorders Center, São Paulo, Brazil

<sup>c</sup> Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour; Department of Rehabilitation, Centre of Expertise for Parkinson & Movement Disorders, Nijmegen, the Netherlands

<sup>d</sup> Sint Maartenskliniek, Department of Rehabilitation, Nijmegen, the Netherlands

e Radboud University Medical Center, Department for Health Evidence, Radboud Institute for Health Sciences, Nijmegen, the Netherlands

### ARTICLE INFO

Keywords: Parkinson's disease Clinical trial Physiotherapy Balance Postural control Cueing Exercises Non-phramacological intervention

### ABSTRACT

Non-pharmacological interventions such as physiotherapy are recognized as important elements in the overall clinical management of motor impairments in PD, but evidence of physiotherapy in advanced disease stages is sparse. A recent trial found positive effects of multimodal balance training in people with mild to moderate PD, with greater and more sustained effects when rhythmical auditory stimuli were added. It is unclear whether such multimodal balance training is also effective in people with advanced PD (Hoehn & Yahr stage 4).

*Methods*: We performed a pilot prospective single-blind, randomized clinical trial to study the effectiveness of multimodal training with and without rhythmical auditory stimuli. We screened 76 people with Parkinson's disease and Hoehn & Yahr stage 4 by telephone; 35 patients were assigned randomly into two groups: (1) multimodal balance training with rhythmical auditory stimuli (RAS-supported intervention, n = 17) and (2) multimodal balance training without rhythmical auditory cues (n = 18). Training was performed for 5 weeks, two times/week. Primary outcome was the Mini-BESTest (MBEST) score immediately after the training period. Assessments were performed by the same two blinded assessors at baseline, immediately post intervention, and after one and 6-months follow-up.

*Results*: Immediately post-intervention, both intervention groups improved significantly on Mini-Best scores, without differences between both intervention modalities. In both groups, results were retained at one-month follow-up. At 6-months follow-up, the effects were retained only in the RAS-supported intervention group. For both intervention groups, no improvements were found on secondary outcome measures for gait.

*Conclusion:* Both RAS-supported multimodal balance training and regular multimodal balance training improve balance in PD patients in advanced disease stages. Effects appear to sustain longer in the RAS-supported training group.

### 1. Introduction

People in late stages of Parkinson's disease (PD) have severe balance and gait impairments which dramatically impact on their quality of life [1–3]. Gait and balance impairments frequently result in falls and fallrelated injuries [4]. Unfortunately, dopaminergic medication has only limited effect on these balance and gait impairments [5,6]. Complementary non-pharmacological interventions, such as physiotherapy, are therefore essential [7]. There is growing evidence to support the role of such non-pharmacological interventions (in particular physiotherapy) in mild and moderate stages of PD [8,9]. Compensation strategies such as rhythmic auditory cueing have an immediate and short effect on walking speed, stride length and cadence [10–16]. However, the evidence of non-pharmacological interventions

\* Corresponding author at: Radboud University Medical Centre, PO Box 9101, 6500, HB, Nijmegen, the Netherlands. *E-mail addresses:* tamine.capato@radboudumc.nl, taminec@usp.br (T.T.C. Capato).

https://doi.org/10.1016/j.jns.2020.117086

Received 27 March 2020; Received in revised form 7 July 2020; Accepted 5 August 2020 Available online 11 August 2020 0022-510X/ © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). for PD in late stages is sparse [11,17–21] and there is a lack of methodological strength.

A recent prospective randomized clinical trial evaluated the efficacy of adding rhythmical auditory stimuli to standard physiotherapy (RASsupported multimodal balance training) by comparing RAS-supported multimodal balance training to multimodal balance training without auditory stimuli and a control group receiving an educational program [22]. Both RAS-supported multimodal training and regular multimodal balance training (without auditory stimuli) improved balance and gait performance after 5 weeks of training, compared to controls. However, the effects were larger for the RAS-supported training group than regular training group. Moreover, only the RAS-supported training group retained the effects at long-term follow-up (6 months). As this trial only included people with mild to moderate PD, the effect of RAS-supported multimodal balance training in patients with more advanced disease stages remains unknown. Here, we therefore investigated the effects of RAS-supported multimodal balance training compared to multimodal balance training without auditory stimuli in people with Hoehn & Yahr stage 4 PD.

#### 2. Methods

### 2.1. Study design and participant

We performed a pilot prospective single-blind, randomized clinical trial between May 2017 and October 2019 at the Movement Disorders Center of the University of São Paulo Faculty Medicine Clinics Hospital. The current study was approved by the local ethical committee (3.986.215), and participants signed an informed consent form before participation. Patients were recruited via the outpatient clinic (either via the treating neurologist, physiotherapist and via a noticeboard in the waiting room) and via posts on social media (Facebook and Instagram). Inclusion criteria were: (1) diagnosis of PD according to the UK Brain Bank criteria [23]; (2) Hoehn and Yahr (H&Y) stage 4 [1]; (3) history of falls (at least once in the previous 12 months); (4) Mini Mental Status Examination (MMSE)  $\geq 15$  [24]; (5) able to walk indoors (either independently, or with supervision, or walking aid); (6) no hearing or visual problems interfering with the tests or training. Exclusion criteria were: (1) unstable medication over the past 3 months; and (2) unstable deep brain stimulator settings during the past year. After the inclusion, no other physiotherapy interventions or complementary exercises were allowed during the study.

### 2.2. Study procedure

After screening for eligibility, subjects were assigned randomly (1:1) into one of the two arms of the intervention (RAS-supported multimodal balance training (experimental group), regular multimodal balance training (control intervention group)). A computerized block randomization procedure (block size 4) was performed by an independent study collaborator before the baseline assessment. Group allocation was performed by the same study collaborator, who was not involved in either of the interventions and assessments. This collaborator delivered a sealed envelope to the physiotherapist to ensure concealment.

All measurements were performed by the same two blinded assessors (physiotherapists) at four time points: baseline, i.e. 14 days prior to training; one day after the last 5th week training; at one-month follow-up; and 6-months follow-up. Both assessors and patients were instructed not to talk about the allocation. We did not formally test for the success of blinding. All participants were tested while they were on their usual Parkinson medication (ON-medication state), which was defined as maximally 1 h after ingestion of their regular dose of dopaminergic medication (as self-reported by the patients) and when patients experienced a subjectively good ON state.

### 2.3. Intervention

Interventions were delivered at the University of São Paulo Clinics Hospital, Movement Disorders Center, Department of Neurology. The two interventions occurred on the same day and at the same location, but during different timeslots during the afternoon. Both experimental groups received balance training; one intervention group received all exercises combined with rhythmical auditory stimuli, provided by a metronome (RAS-supported multimodal balance intervention, see Supplementary Video S1), whereas the other intervention group received balance training without rhythmical auditory stimuli (regular multimodal balance training (control intervention)). Both intervention groups also received gait training with visual cues (as this is part of routine physiotherapy care based on the European guideline for physiotherapy in PD [25,26]), but rhythmical auditory stimuli to augment the balance exercises were only added in the RAS-supported group on top of the training. The physiotherapist gave instructions to the patients to perform the movements by following the beat of the metronome. The training program was performed in groups of four participants, supervised by two physiotherapists to ensure safety. Training in both intervention groups involved 20 balance and gait exercises, provided during 10 sessions of 45 min (2 sessions/week over a 5-week period). The exercises, training progression and intensity are described in Supplementary Table 1 and 2. The rhythmical auditory stimuli were delivered in an open-loop by a metronome and in a personalized manner when the patient was not able to perform the movement safely or with good quality. We used a MA-1 KOR metronome, with amplifier model JBL GO Portable Wireless Speaker. Progression over time was facilitated by dividing the training period into two 5-week sessions. Each exercise component was introduced separately to the participants in week 1, with emphasis on the quality of performance rather than on difficulty level. In week 2, the level of difficulty for each exercise component was increased, whereas movement complexity was further increased in week 3, 4 and 5 by combining the exercise components and increasing the demands. To further promote training progression, the aim was to increase or decrease the speed throughout the parts of the training.

### 2.4. Outcome measures

The primary outcome was Mini-BESTest (MBEST) [27]. Secondary outcomes included measures of balance and gait: Berg Balance Scale (BBS) [42], Timed Up and Go Test (TUG) [45], TUG-dual task condition (14 domain in MBEST) [41] and Rapid Turns Test [37] and New Freezing of Gait Questionnaire (N-FOGQ) [36]. Activities of daily living and motor performance were assessed using the MDS-UPDRS part 2 and part 3 [28]. Fear of falling was evaluated using the Falls Efficacy Scale-International (FES–I) [46]. To optimally reflect common daily practice, treating physicians were allowed to make medication adjustments during the course of the physiotherapy intervention if this was deemed clinically necessary. To control for the possible effect of this, the levodopa equivalent daily dose (LEDD) was reported by interview (patients and caregivers) and was checked using patient's medical reports. Falls and serious adverse events were assessed and monitored through standardized weekly interviews.

### 2.5. Statistical analysis

Statistical analysis was performed according the intention-to-treat (ITT) principle which was defined as all patients who were allocated to the intervention, had a full baseline assessment, and from whom at least one measurement after baseline was obtained. Linear mixed models were used for all outcomes. The primary endpoint was the MBEST score immediately post-intervention. We used treatment (RAS-supported multimodal balance training vs. regular multimodal balance training), visit (immediately post-intervention, one-month follow-up, and




Fig. 1. Flow diagram of participants through the trial, number of participants.

6 months follow-up) and the interaction between visit and treatment group as fixed factors. The model was adjusted for baseline MBEST, MDS-UPDRS part 2 and 3 and levodopa equivalent daily dose (LEDD), and for the baseline value of the dependent variable. Patient was included as a random factor. A Bonferroni adjustment for multiple testing (three pairwise comparisons at 5 weeks follow-up) was applied, resulting in a significance threshold of 0.017 that was used for all tests. No interim analyses were performed.

### 3. Results

We screened 76 potential candidates, and 35 were randomized (of which 23 were recruited from outside the outpatient clinic) (Fig. 1). Reasons for others subjects not being included were not meeting inclusion criteria, no stable DBS-setting, excessive low back pain, unable to attend training schedule and problems with transportation. Both intervention groups were similar on baseline characteristics (Table 1). A total of 7 patients dropped out of the study (Fig. 1). Reasons for not being compliant (20%) were lack of time, problems with transport, injuries not related to the intervention, or illness and fatigue not related to the intervention occurred during the study period.

### 3.1. Primary outcome

Fig. 2 shows the results on our primary outcome, the MBEST. Immediately post-intervention, both intervention groups improved significantly on Mini-Best scores, without significant differences between both groups. In both groups, results were retained at one-month followup. At 6-months follow-up, however, the effects were retained only in the RAS-supported intervention group (Table 2).

# Table 1 A. Participants' characteristics at the baseline visit, Hoehn & Yahr stage 4.

	Multimodal $N = 17$	Standard $N = 18$
Age, years (mean (SD))	77 (7)	78 (10)
Gender, men (N (%))	9 (53%)	12 (66%)
Disease duration (mean (SD))	17 (9)	11 (4)
LEDD, mg/day (mean (SD))	749 (381)	869 (327)
MMSE, score (mean (SD))	21 (3)	18 (6)
MoCA, score (mean (SD))	19 (5)	18 (5)
MDS-UPDRS 2, ADL score (mean (SD)) (ON)	22 (6)	20 (7)
MDS-UPDRS 3, motor score (mean (SD)) (ON)	38 (8)	35 (9)

Group: Multimodal Training Group (MT), Standard training Group (ST), N, number of participants; SD, *Standard Deviation*; ON (ON-medication); LEDD, levodopa equivalent daily dose; MMSE, Mini Mental State Examination; MoCA, Montreal Cognitive Assessment; MDS-UPDRS 2, ADL, Activities of daily living score; MDS-UPDRS 3, motor score.

### 3.2. Secondary outcomes

### 3.2.1. Balance

Only the RAS-supported intervention group improved immediately post-intervention on the Berg Balance Scale. Improvements were retained at one-month and 6-month follow-up (Table 2). In both intervention groups, no improvements were found on FES-I. Fewer falls and severe injuries (outside the intervention) were reported after the intervention by all groups.

### 3.2.2. Gait

No significant improvements or differences were found on TUG in both intervention groups at all time points. Also, no improvements or differences were observed in the TUG Dual Task and N-FOGQ (Table 2).

### Primary Outcome - MBEST (H&Y4)




Table 2

Observed mean values and estimated differences and 95% confidence intervals for primary and secondary outcome measures.

Baseline Post Intervention 1-month Follow-up 6-months Follow-up Baseline	RAS-supported 1 9.6 (7.7; 11.5) 15.2 (13.4; 17.1) 14.2 (14.3; 16.5) 12.4 (12.7; 14.8)	Regular 2 12.8 (9.9; 15.7) 16.6 (12.8; 16.2) 16.0 (12.0; 15.4)	RAS-supported vs Regular 1–2 1.4 (-0.1; 3.0), P = 0.070
Post Intervention 1-month Follow-up 6-months Follow-up Baseline	15.2 (13.4; 17.1) 14.2 (14.3; 16.5)	16.6 (12.8; 16.2)	1.4(-0.1; 3.0), P = 0.070
1-month Follow-up 6-months Follow-up Baseline	14.2 (14.3; 16.5)		1.4(-0.1; 3.0), P = 0.070
6-months Follow-up Baseline		16 0 (12 0, 15 4)	
Baseline	12.4 (12.7; 14.8)	16.0 (13.0; 15.4)	1.2(-0.4; 2.8), P = 0.133
		13.5 (10.2; 12.5)	2.3 (0.7; 3.9), P = 0.005
D . I	29.0 (24.6; 33.0)	37.5 (32.8; 42.3)	
Post Intervention	37.7 (33.2; 42.2)	39.0 (33.9; 44.0)	3.9(0.0; 7.9), P = 0.049
1-month Follow-up	36.8 (31.9; 41.7)	37.4 (32.1; 42.8)	3.9(0.0; 7.9), P = 0.051
6-months Follow-up	33.1 (28.3; 37.9)	35.3 (29.9; 40.6)	2.6(-1.3; 6.6), P = 0.183
Baseline	37.1 (28.0; 46.2)	48.3 (39.0; 57.5)	
Post Intervention	35.8 (25.5; 46.1)	42.5 (35.7; 49.8)	0.8 (8.1; 9.8), P = 0.853
1-month Follow-up	36.4 (26.1; 46.7)	42.8 (35.7; 49.9)	1(-7.9; 10.4), P = 0.812
6-months Follow-up	39.6 (29.8; 49.4)	48.0 (40.6; 55.3)	-4.2(-13.0; 4.7), P = 0.336
Baseline	29.8 (22.1; 37.4)	26.2 (17.9; 34.6)	
Post Intervention		. , ,	-3.8(-8.2; 0.5), P = 0.065
1-month Follow-up		. , ,	-2.1(-6.4; 2.2), P = 0.324
1			-3.3(-7.5; 0.9), P = 0.124
-		34.5 (20.5; 48.6)	
Post Intervention		36.4 (17.5; 55.2)	-2.6(-11.96.6), P = 0.567
1-month Follow-up			0.3(-9.0; 9.7), P = 0.942
1		. , ,	-0.3(-9.4; 9.3), P = 0.994
1		. , ,	
Post Intervention	11.2 (4.7; 17.6)	8.3 (3.3; 13.22)	-0.8(-3.3; 1.7), P = 0.518
1-month Follow-up			0.4(-2.0; 3.0), P = 0.697
1			0.8(-1.6; 3.4), P = 0.476
•			
Post Intervention	. , ,		-49.9(-119.5; 19.6), P = 0.156
		. , ,	-33.1 (-102; 36.4), P = 0.343
1	. , ,		-29.9(-99.1; 40.0), P = 0.398
1	. , ,		
Post Intervention			-1.5(-2.6; -3.7), P = 0.010
1-months Follow-up		. , ,	-1.1(-2.3; -0.4), P = 0.042
1			-0.5(-1.6; 0.6), P = 0.398
•			
		. , ,	-1.4(-2.4; -0.3), P = 0.011
			-1.3(-2.4; -0.2), P = 0.018
		. , ,	-0.7 (-0.3; 1.8), P = 0.157
	6-months Follow-up Baseline Post Intervention 1-month Follow-up Baseline Post Intervention 1-month Follow-up 6-months Follow-up 6-months Follow-up Baseline Post Intervention 1-months Follow-up 6-months Follow-up Baseline Post Intervention 1-month Follow-up 6-months Follow-up Baseline Post Intervention 1-month Follow-up 6-months Follow-up 6-months Follow-up 6-months Follow-up	Baseline       37.1 (28.0; 46.2)         Post Intervention       35.8 (25.5; 46.1)         1-month Follow-up       36.4 (26.1; 46.7)         6-months Follow-up       39.6 (29.8; 49.4)         Baseline       29.8 (22.1; 37.4)         Post Intervention       23.6 (16.5; 29.4)         1-month Follow-up       25.8 (17.8; 33.8)         6-months Follow-up       27.5 (19.5; 35.5)         Baseline       43.2 (29.0; 57.3)         Post Intervention       35.2 (23.1; 47.4)         1-month Follow-up       40.3 (23.2; 57.3)         6-months Follow-up       45.7 (26.5; 64.8)         Baseline       14.3 (6.7; 21.8)         Post Intervention       11.2 (4.7; 17.6)         1-month Follow-up       11.8 (4.7; 18.9)         6-months Follow-up       13.7 (5.8; 21.6)         Baseline       794 (668; 919)         Post Intervention       803 (668; 938)         1-month Follow-up       803 (668; 938)         6-months Follow-up       830 (668; 972)         Baseline       22.4 (19.43; 25.5)         Post Intervention       21.4 (18.8; 24.7)         1-months Follow-up       23.7 (19.8; 27.5)         Post Intervention       21.4 (18.8; 24.7)         1-months Follow-up       23.7	Baseline       37.1 (28.0; 46.2)       48.3 (39.0; 57.5)         Post Intervention       35.8 (25.5; 46.1)       42.5 (35.7; 49.8)         1-month Follow-up       36.4 (26.1; 46.7)       42.8 (35.7; 49.9)         6-months Follow-up       39.6 (29.8; 49.4)       48.0 (40.6; 55.3)         Baseline       29.8 (22.1; 37.4)       26.2 (17.9; 34.6)         Post Intervention       23.6 (16.5; 29.4)       26.8 (14.7; 37.7)         1-month Follow-up       25.8 (17.8; 33.8)       26.7 (15.2; 38.2)         6-months Follow-up       27.5 (19.5; 35.5)       29.6 (19.0; 40.1)         Baseline       43.2 (29.0; 57.3)       34.5 (20.5; 48.6)         Post Intervention       35.2 (23.1; 47.4)       36.4 (17.5; 55.2)         1-month Follow-up       40.3 (23.2; 57.3)       37.0 (18.3; 55.7)         6-months Follow-up       45.7 (26.5; 64.8)       42.2 (22.0; 62.4)         Baseline       14.3 (6.7; 21.8)       8.9 (3.9; 13.9)         Post Intervention       11.2 (4.7; 17.6)       8.3 (3.3; 13.22)         1-month Follow-up       13.7 (5.8; 21.6)       10.0 (4.6 15.3)         Baseline       794 (668; 919)       869 (693; 1046)         Post Intervention       803 (668; 938)       941(686; 1197)         1-month Follow-up       803 (668; 938)       941(686

Group: Multimodal balance training supported by rhythmical auditory stimuli (RAS-supported), Multimodal balance training without rhythmical auditory stimuli (Regular). Confidence Intervals (CI) –Adjusted Mean Difference (95% CI) Between Baseline and 35-week. Primary analysis: Adjusted for baseline MBEST score; Secondary analyses: also adjusted for baseline LEDD, baseline MDS-UPDRS 2 and 3. Mini BESTest – 14 items, total 28 of points, scored 0–2 (higher score better balance). Berg Balance Scale - 14 items total 56 of points, scored 0–4 points (higher score better balance). Falls Efficacy Scale International – 16 items, total 64 of points scored 1-), higher scores greater fear of fallen. TUG and TUGDT were measured in time in seconds (time in seconds is the unit) with a range from 5 to 60 s (which is the range). A lower score means better mobility. N-FOGQ - 10 items, total 29 of points, scored 0–3 or 4. A lower score, less freezing problems.

### 3.2.3. Levodopa equivalent daily dose (LEDD)

The LEDD was not significantly different between RAS-supported and regular intervention groups for either of the follow-up moments post-intervention (Table 2).

### 3.2.4. MDS-UPDRS

For both intervention groups, no improvements were observed when looking at MDS-UPDRS part 2 scores (Table 2). Only the RASsupported intervention group improved on the MDS-UPDRS part 3 immediately post-intervention, which was maintained at one month follow-up, but not at 6-months follow-up (Table 2).

### 4. Discussion

Here, we investigated the effects of RAS-supported multimodal balance training compared to multimodal balance training without auditory stimuli in people with PD and in H&Y stage 4. Our study shows for the first time that specialized physiotherapy with a specific protocol of exercises with RAS can improve balance performance in PD patients in advanced disease stages and mild cognitive decline. Only a few rehabilitation studies have included a subgroup of H&Y4 patients [20,29–31], but no studies have focused specifically on balance training with RAS on advanced disease stages (H&Y4).

Our study highlights that multimodal balance training (both with and without rhythmical auditory stimuli) is feasible in patients with advanced disease stages, as it did not result in falls and serious adverse events. The minimally clinically relevant difference for the MBEST test in PD is 3.4 points [32], and the minimal detectable change is 3 to 3.5 [32–34], which means that the average improvement (both immediately post-intervention and at one-month follow-up) exceeded these values in both intervention groups. Our secondary analyses suggest that retention at six-month follow-up is larger in the RAS-supported multimodal balance training group compared to the multimodal balance training without auditory stimuli, but these findings should be replicated in future trials.

Using rhythmic auditory cues may improve training effects by making it more explicit than training without auditory cues (regular training or conventional therapy) [13,22,35]. By doing so, PD patients may shift their habitual motor control (predominantly relying on the posterior putamen) to more goal-directed motor control (involving the anterior putamen), thereby improving motor learning [36]. Additionally, cueing may improve attention and task prioritization (better executive control) [37–39], thereby helping to prioritize balance control over other tasks. External cues may also serve as an external reward, thereby further facilitating the learning processes [40].

In compare to our previous study with patients in early and moderate disease stages [22], no significant improvements on secondary gait-related outcomes was found. The lack of effects on gait speed outcomes in both groups may indicate that patients in advanced disease stages experience difficulties to transfer balance improvements to gait tasks. Moreover, gait not only depends on balance control [41,42], but also on several other factors such as motor control and executive function [41–44], which are frequently impaired in advanced disease stages [3]. Alternatively, our study may have been underpowered to detect differences (this was a pilot exploratory study), as a trend towards improvement was observed in the RAS-supported intervention group.

Our study is not without limitations. First, our study lacks a control group receiving no intervention. Second, as indicated above, our sample size was relatively small, and our study may have been underpowered to detect differences on secondary outcomes. Studies with large samples are therefore needed, using the present outcomes as input for the power analysis. Larger future studies may also perform a correlation or regression analysis to evaluate which patient characteristics influence the results. Finally, we did not investigate the RAS-supported multimodal balance training effect on quality of life, which could be an important determinant of the efficacy of physiotherapy. This aspect deserves further investigation in future studies.

Taken together, our findings further support the importance of nonpharmacological intervention in the management of axial problems as gait and balance in PD patients in advanced stages (H&Y4). Current physiotherapy guidelines [26,45] provide no recommendations on specific approach for the H&Y4 subgroup. The present results, indicating that multimodal balance intervention (combined with rhythmical auditory cues) is effective, can help to fill this gap and contribute to an increasing evidence base for physiotherapy, eventually leading to optimized care for PD patients in advanced stages. The field of physiotherapy and rehabilitation generally needs more studies to determine the long-term effects, and to identify how any initially achieved clinical improvements can be maintained in the long term. Concerns about a possible tapering of improvements over time may apply in particular to the more vulnerable group of patients with advanced disease. The RASsupported intervention that we tested here is no exception. Future studies should therefore also evaluate how often a RAS-therapy should be repeated in patients with advanced disease stages (e.g. continuous training sessions twice a week, or '10 boost-sessions' every 6 months).

### Acknowledgements

The Radboudumc Center of Expertise for Parkinson & Movement Disorders was supported by a Center of Excellence grant of the Parkinson's Foundation.

The authors thank all the patients who participated in this study, as well as all trainers, testers and collegues from University of São Paulo. We also thank the suport of PHYSICAL Parkinson's Disease and Movement Disorders Rehabilitation Center, São Paulo, Brazil.

### Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jns.2020.117086.

### References

- M.M. Hoehn, M.D. Yahr, Parkinsonism: onset, progression and mortality, Neurology 17 (5) (1967) 427–442.
- [2] M. Coelho, et al., Treatment options for non-motor symptoms in late-stage Parkinson's disease, Expert. Opin. Pharmacother. 9 (4) (2008) 523–535.
- [3] M. Fabbri, et al., Do patients with late-stage Parkinson's disease still respond to levodopa? Parkinsonism Relat. Disord. 26 (2016) 10–16.
- [4] B.R. Bloem, et al., Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena, Mov. Disord. 19 (8) (2004) 871–884.
- [5] S.H. Fox, et al., International Parkinson and movement disorder society evidencebased medicine review: update on treatments for the motor symptoms of Parkinson's disease, Mov. Disord. 33 (8) (2018) 1248–1266.
- [6] M.J. Armstrong, M.S. Okun, Diagnosis and treatment of Parkinson disease: a review, Jama 323 (6) (2020) 548–560.
- [7] J. Nonnekes, A. Nieuwboer, Towards personalized rehabilitation for gait impairments in Parkinson's disease, J. Park. Dis. 8 (s1) (2018) S101–s106.
- [8] B.R. Bloem, N.M. de Vries, G. Ebersbach, Nonpharmacological treatments for patients with Parkinson's disease, Mov. Disord. 30 (11) (2015) 1504–1520.
- [9] J. Domingos, et al., The European physiotherapy guideline for Parkinson's disease: implications for neurologists, J. Park. Dis. 8 (4) (2018) 499–502.
- [10] P. Ginis, et al., Cueing for people with Parkinson's disease with freezing of gait: a narrative review of the state-of-the-art and novel perspectives, Ann Phys Rehabil Med 61 (6) (2017) 407–413.
- [11] A. Nieuwboer, et al., Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial, J. Neurol. Neurosurg. Psychiatry 78 (2) (2007) 134–140.
- [12] I. Lim, et al., Effects of external rhythmical cueing on gait in patients with
- Parkinson's disease: a systematic review, Clin. Rehabil. 19 (7) (2005) 695–713.
  [13] S. Ghai, et al., Effect of rhythmic auditory cueing on parkinsonian gait: a systematic review and meta-analysis, Sci. Rep. 8 (1) (2018) 506.
- [14] Z. Kadivar, et al., Effect of step training and rhythmic auditory stimulation on functional performance in Parkinson patients, Neurorehabil. Neural Repair 25 (7) (2011) 626–635
- [15] J.H. Song, et al., Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease, Eur. Rev. Med. Pharmacol. Sci. 19 (11) (2015) 2001–2007.
- [16] M.J. Hove, et al., Interactive rhythmic auditory stimulation reinstates natural 1/f

timing in gait of Parkinson's patients, PLoS One 7 (3) (2012) e32600.

- [17] M. Balzer-Geldsetzer, et al., Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study, BMC Neurol. 18 (1) (2018) 185.
- [18] A.E. Jacob, et al., Motor retraining (MoRe) for functional movement disorders: outcomes from a 1-week multidisciplinary rehabilitation program, Pm r 10 (11) (2018) 1164–1172.
- [19] Y. Kaseda, et al., Therapeutic effects of intensive inpatient rehabilitation in advanced Parkinson's disease, Neurol Clin Neurosci 5 (1) (2017) 18–21.
- [20] A. Ashburn, et al., A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson's disease, J. Neurol. Neurosurg. Psychiatry 78 (7) (2007) 678–684.
- [21] V. Studer, et al., Treadmill training with cues and feedback improves gait in people with more advanced Parkinson's disease, J. Park. Dis. 7 (4) (2017) 729–739.
- [22] T.T.C. Capato, et al., Multimodal balance training supported by rhythmical auditory stimuli in Parkinson's disease: a randomized clinical trial, J. Park. Dis. 10 (1) (2020) 333–346.
- [23] A.J. Hughes, et al., Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, J. Neurol. Neurosurg. Psychiatry 55 (3) (1992) 181–184.
- [24] T.N. Tombaugh, N.J. McIntyre, The mini-mental state examination: a comprehensive review, J. Am. Geriatr. Soc. 40 (9) (1992) 922–935.
- [25] S. Keus, et al., European physiotherapy guideline for Parkinson's disease, (2014).
  [26] T. Capato, J. D. L. Almeida, Versão em Português da Diretriz Europeia de
- Fisioterapia para Doença de Parkinson, ed. 1, Vol. 1 (2015), p. 202 São Paulo: Ominifarma.
  [27] F. Franchignoni, et al., Using psychometric techniques to improve the balance
- evaluation systems test: the mini-BESTest, J. Rehabil. Med. 42 (4) (2010) 323–331. [28] C.G. Goetz, et al., Movement Disorder Society-sponsored revision of the unified
- Parkinson's disease rating scale (MDS-UPDRS): scale presentation of the uninted Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results, Mov. Disord. 23 (15) (2008) 2129–2170.
- [29] N. Smania, et al., Effect of balance training on postural instability in patients with idiopathic Parkinson's disease, Neurorehabil. Neural Repair 24 (9) (2010) 826–834.
- [30] K.S. Rawson, et al., Exercise and Parkinson disease: comparing tango, treadmill, and stretching, J. Neurol. Phys. Ther. 43 (1) (2019) 26–32.
- [31] P. Ortelli, et al., Effectiveness of a goal-based intensive rehabilitation in Parkinsonian patients in advanced stages of disease, J. Park. Dis. 8 (1) (2018)

113–119.

- [32] N. Lofgren, et al., The mini-BESTest-a clinically reproducible tool for balance evaluations in mild to moderate Parkinson's disease? BMC Neurol. 14 (2014) 235.
- [33] C.S. Tsang, et al., Psychometric properties of the mini-balance evaluation systems test (mini-BESTest) in community-dwelling individuals with chronic stroke, Phys. Ther. 93 (8) (2013) 1102–1115.
- [34] M.T. Barbosa, et al., Prevalence and clinical classification of tremor in elderly-a community-based survey in Brazil, Mov. Disord. 28 (5) (2013) 640–646.
- [35] M. Murgia, et al., The use of footstep sounds as rhythmic auditory stimulation for gait rehabilitation in Parkinson's disease: a randomized controlled trial, Front. Neurol. 9 (2018) 348.
- [36] M. Olson, T.E. Lockhart, A. Lieberman, Motor learning deficits in Parkinson's disease (PD) and their effect on training response in gait and balance: a narrative review, Front. Neurol. 10 (2019) 62.
- [37] L. Rochester, et al., Does auditory rhythmical cueing improve gait in people with Parkinson's disease and cognitive impairment? A feasibility study, Mov. Disord. 24 (6) (2009) 839–845.
- [38] V.E. Kelly, A.J. Eusterbrock, A. Shumway-Cook, A review of dual-task walking deficits in people with Parkinson's disease: motor and cognitive contributions, mechanisms, and clinical implications, Parkinsons Dis 2012 (2012) 918719.
- [39] B.R. Bloem, et al., The "posture second" strategy: a review of wrong priorities in Parkinson's disease, J. Neurol. Sci. 248 (1–2) (2006) 196–204.
- [40] L. Marinelli, et al., The many facets of motor learning and their relevance for Parkinson's disease, Clin. Neurophysiol. 128 (7) (2017) 1127–1141.
- [41] F.B. Horak, et al., Balance and gait represent independent domains of mobility in Parkinson disease, Phys. Ther. 96 (9) (2016) 1364–1371.
- [42] J.H. Park, Y.J. Kang, F.B. Horak, What is wrong with balance in Parkinson's disease? J Mov Disord 8 (3) (2015) 109–114.
- [43] N. Giladi, F.B. Horak, J.M. Hausdorff, Classification of gait disturbances: distinguishing between continuous and episodic changes, Mov. Disord. 28 (11) (2013) 1469–1473.
- [44] D.S. Peterson, et al., Cognitive contributions to freezing of gait in Parkinson disease: implications for physical rehabilitation, Phys. Ther. 96 (5) (2016) 659–670.
- [45] S. Keus, et al., European Physiotherapy Guideline for Parkinson's Disease, KNGF/ ParkinsonNet (2014).